Seres Therapeutics holds annual shareholder meeting

Seres Therapeutics held its 2026 annual shareholder meeting on July 8, 2026. Shareholders approved an amended and restated 2025 Incentive Award Plan, increasing the share pool by 900,000 shares. The board authorized this change on April 22, 2026, pending shareholder adoption. The filing confirms no awards have been issued yet.

Seres Therapeutics held its 2026 annual shareholder meeting on July 8, 2026. * Shareholders adopted an amended and restated 2025 Incentive Award Plan, increasing the share pool by 900,000 shares. * The plan change was authorized by the board on April 22, 2026, subject to shareholder adoption; the filing does not confirm any awards were issued. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-298525), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Seres Therapeutics held its 2026 annual shareholder meeting on July 8, 2026. * Shareholders adopted an amended and restated 2025 Incentive Award Plan, increasing the share pool by 900,000 shares. * The plan change was authorized by the board on April 22, 2026, subject to shareholder adoption; the filing does not confirm any awards were issued. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-298525), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here